Author

K. Tyryshkin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. Koti· 4 shared S. Chenard· 3 shared A. Garven· 2 shared A. Hamade· 2 shared B. J. Laight· 2 shared D. Li· 2 shared D. M. Berman· 2 shared G. Conseil· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Koti

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Fes-deficient macrophages enhance CD8+ T cell priming and tumour control through increased proinflammatory cytokine production and localization

B. J. Laight, D. Harper, N. Dmytryk, S. Zhang, A. Garven, C. Shi, R. Nauman, J. Kment, F. Alotaibi, I. Shapovalov, Y. Gao, J. Mewburn, C. Vlasschaert, D. LeBrun, K. Tyryshkin, , P. A. Greer

bioRxiv · Feb 27, 2024 · PreprintImmunology

Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancer

B. Ravenscroft, P. Yolmo, S. Chenard, S. Rahimi, K. Pace, K. Sachdeva, T. Jamaspishvilli, H. Ghadei, A. Garven, K. Tyryshkin, D. M. Berman, C. Jackson, D. R. Siemens, M. Koti

This study identifies increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages as predictors of poor clinical outcomes in BCG-treated NMIBC patients.

bioRxiv · Oct 19, 2023 · PreprintCancer Biology

PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer

N. Shakfa, D. Li, G. Conseil, E. D. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, B. J. Laight, A. Asante, K. Tyryshkin, M. Köbel, M. Koti

This study examines how PTEN and BRCA1 loss in ovarian cancer affects tumor immune microenvironment response to STING pathway activation, showing improved survival in PTEN-deficient tumors with STING therapy.

bioRxiv · Jun 27, 2022 · PreprintImmunology

The influence of age and sex on the pre-treatment immune microenvironment of a carcinogen induced murine model of bladder cancer

A. Hamade, D. Li, K. Tyryshkin, M. Xu, S. Chenard, G. Conseil, P. Yolmo, R. Siemens, M. Koti

This study examines sex and age-related immune differences in healthy and carcinogen-exposed murine bladders using bulk RNA sequencing and spatial immune profiling.

bioRxiv · Sep 10, 2021 · PreprintCancer Biology